RxSight(US:RXST) Globenewswire·2026-01-11 14:30Core Viewpoint - RxSight, Inc. has announced preliminary unaudited financial and operational results for Q4 and full-year 2025, indicating a positive trajectory in patient treatment and market share despite challenges faced during the year [1][3][8]. Financial Results - Preliminary unaudited revenue for Q4 2025 is expected to be approximately $32.6 million, driven by the sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®), representing a 10% increase in procedure volume compared to Q3 2025 [8]. - Preliminary unaudited revenue for the full year 2025 is expected to be approximately $134.5 million, exceeding previous guidance of $125 to $130 million, with a 12% increase in procedure volume compared to 2024 [8]. - The company installed 1,134 Light Delivery Devices (LDDs) by the end of 2025, with a total of 163 LDDs sold during the year [8]. Market Position and Growth - RxSight holds approximately 10% market share in the premium intraocular lens (IOL) market, with adoption by over 25% of U.S. cataract surgeons [3]. - The company has made significant progress in treating more patients than ever before, positioning itself for sustained long-term growth [3]. Leadership Transition - Mark Wilterding has been appointed as the new Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience [4][5]. - Wilterding's previous role was Senior Vice President of Global Finance for Edwards Lifesciences, where he oversaw various financial operations [5]. Future Outlook - The company is set to announce audited full-year 2025 financial results and guidance for 2026 in February 2026 [7][8].